Neuropace Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.86.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Neuropace Inc is 6.61, ranking 135 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 22.07M, representing a year-over-year decrease of 2.02%, while its net profit experienced a year-over-year decrease of 1.52%.
Key Metrics
The current valuation score of Neuropace Inc is 7.15, ranking 119 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -23.81, which is -96.84% below the recent high of -0.75 and -23.50% above the recent low of -29.41.
The current earnings forecast score of Neuropace Inc is 8.50, ranking 27 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 18.00, with a high of 20.00 and a low of 15.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Neuropace Inc is 7.09, ranking 63 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 18.76 and the support level at 12.81, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Neuropace Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 99.26%, representing a quarter-over-quarter increase of 7.21%. The largest institutional shareholder is Paul Tudor Jones, holding a total of 193.35K shares, representing 0.57% of shares outstanding, with 289.00% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Neuropace Inc is 3.82, ranking 117 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.91. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Neuropace Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
